<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399672</url>
  </required_header>
  <id_info>
    <org_study_id>C06-0192</org_study_id>
    <nct_id>NCT00399672</nct_id>
  </id_info>
  <brief_title>Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)</brief_title>
  <official_title>Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although injection drug users (IDUs) account for over 70% of new cases of HCV infection/year,&#xD;
      there is no consensus on how to approach their medical care. In some Canadian centres,&#xD;
      patients must be free of recreational drug use for as long as 6 months before being&#xD;
      considered for HCV therapy. This is not consistent with current North American guidelines.&#xD;
      Over the past 5 years, we have developed a successful program for the treatment of HIV&#xD;
      infection in this population, based on a multi-disciplinary comprehensive program including&#xD;
      directly observed therapy (DOT). Even though the duration of therapy for HCV is shorter than&#xD;
      for HIV (as little as 6 months vs. life-long), we must address issues of administration of a&#xD;
      weekly injection (interferon), twice daily pills (ribavirin) and the risk of significant side&#xD;
      effects (including anxiety and depression) to successfully expand our program to treat this&#xD;
      disease. Further, it may be that even if the program is successful, its benefits will be&#xD;
      negated by HCV re-infection due to continued risk behaviors for its transmission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will determine the HCV infection status of potential study subjects within a cohort of&#xD;
      2,000 IDUs receiving care in our centres (Appendix 1). For those who carry HCV antibodies&#xD;
      (expected n = 1800), a test for HCV viremia and genotype will be performed. By these&#xD;
      evaluations, we expect up to 600 individuals to be viremic and carry HCV genotype 2 or 3.&#xD;
      Within this group, 200 consecutive patients (100/study strategy) will receive therapy for&#xD;
      HCV, based on their eligibility to do so according to Provincial guidelines for the&#xD;
      reimbursement of medications. Patient allocation will be according to the study site where&#xD;
      they regularly receive care. At two sites, patients will be enrolled in a DOT program with&#xD;
      on-site full-time nursing and counseling support (high intensity, 50 patients/site). At the&#xD;
      other two sites, patients will receive medication on a weekly basis and will have access to&#xD;
      part-time nursing and counseling support (low intensity, 50 patients/site). Medical follow-up&#xD;
      will be according to current clinical standards, and the primary endpoint of the study will&#xD;
      be the rate of sustained virologic response (SVR) six months after completion of treatment.&#xD;
      Within the study described above, we will use standardized methodologies to calculate the&#xD;
      total health care costs related to the treatment of HCV infection. We will also assess the&#xD;
      effect of treatment on the quality of life (QoL) of study participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of sustained virologic response (SVR) six months after completion of treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 4 participating sites are designated either High Intensity or Low Intensity. High Intensity sites have access to: full time specialist physicians, access to full time nurses and counselors. All weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 4 participating sites are designated either High Intensity or Low Intensity. In the Low intensity group, all patients will have access to: full time primary care physicians, specialist physicians and access to part time nurse or counselor by appointment. Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon injections and ribavirin</intervention_name>
    <description>Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon injections and ribavirin</intervention_name>
    <description>Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 19 years;&#xD;
&#xD;
          -  Serum HCV-RNA pos;&#xD;
&#xD;
          -  HCV genotype 2 or 3;&#xD;
&#xD;
          -  HBsAg neg;&#xD;
&#xD;
          -  serum ALT &gt; 1.5x upper limit normal &gt; 3 months;&#xD;
&#xD;
          -  Illicit drug use in the past year;&#xD;
&#xD;
          -  Agreement from each participant of childbearing age to practice contraception;&#xD;
&#xD;
          -  Absence of other contraindications to the initiation of therapy as determined by the&#xD;
             health care team;&#xD;
&#xD;
          -  Ability to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any cause for chronic liver disease other than HCV (including alcohol use &gt;350 g/wk);&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Active HBV infection;&#xD;
&#xD;
          -  Hemolytic anemia;&#xD;
&#xD;
          -  Decompensated cirrhosis or portal hypertension or PT-INR &gt; 1.3 or Child-Hugh class &gt;&#xD;
             A;&#xD;
&#xD;
          -  Active suicidal ideation, psychosis, mania or hypomania;&#xD;
&#xD;
          -  Serum creatinine &gt; 180 Âµg/mL;&#xD;
&#xD;
          -  Hemoglobin &lt; 120 g/L in men or 110 g/L in women;&#xD;
&#xD;
          -  Platelets &lt; 90 x 109/L;&#xD;
&#xD;
          -  Neutrophils &lt; 1.5 x 109/L;&#xD;
&#xD;
          -  Active autoimmune disease;&#xD;
&#xD;
          -  NYHA disease &gt; grade 2;&#xD;
&#xD;
          -  Psoriasis requiring systemic therapy;&#xD;
&#xD;
          -  Active malignancy apart from non melanoma skin cancer;&#xD;
&#xD;
          -  Use of systemic immunosuppressant agents;&#xD;
&#xD;
          -  Prior treatment of HCV with interferon or ribavirin;&#xD;
&#xD;
          -  HIV positive with CD4 count &lt;300 cells/mm3 or receiving didanosine (due to interaction&#xD;
             with ribavirin);&#xD;
&#xD;
          -  Life expectancy &lt; 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Conway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pender Community Health Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6B 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 14, 2006</study_first_submitted>
  <study_first_submitted_qc>November 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2006</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>injection drug users</keyword>
  <keyword>ribavirin</keyword>
  <keyword>pegylated interferon</keyword>
  <keyword>illicit drug users</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

